Related Experiment Video
Updated: Jun 27, 2026

Lexical Decision Task for Studying Written Word Recognition in Adults with and without Dementia or Mild Cognitive Impairment
Published on: June 25, 2019
REAl world Dementia OUTcomes (READ-OUT) protocol: observational study
David J Whiteside1,2, Yi Yang3, Ahmet Begde3
1Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK djw216@cam.ac.uk.
Introduction:
Developments in blood biomarkers (BBMs) in dementia call for studies that evaluate their diagnostic, prognostic and societal implications in real-world populations. Such evidence is essential to support the safe and effective integration of BBMs into clinical practice.
Methods And Analysis:
The REAl world Dementia OUTcomes study (READ-OUT) is a UK-based, multi-site study that assesses the prognostic and diagnostic utility of BBMs in people attending memory assessment services ('secondary care'). READ-OUT phase 1 is a 3-year observational study of 3165 people representative of the UK population, with up-sampling of under-represented groups and proactive recruitment to include individuals missing from secondary care memory services. Participants are over the age of 45, able to provide a blood sample and willing to consent to linkage with electronic health records. The baseline study visit includes venepuncture and questionnaire assessment of quality of life and health resource usage. A subsample of the full cohort will have further venepuncture and questionnaires at a 52-week follow-up. READ-OUT substudies will evaluate BBMs' test-retest reliability, the impact of processing delays and the feasibility of self-collected blood-spot samples. The clinical utility of BBMs will be assessed against diagnosis, outcomes from electronic health records, corollary data and health economic data. Results of the observational study discussed in this protocol will inform the design of a randomised controlled trial to test the cost-effectiveness, acceptability and clinical utility of disclosed BBM results.
Ethics And Dissemination:
The study has received Research Ethics Committee approval (REC reference 24/WA/0330) and approval through the Health Research Authority/Health and Care Research Wales (IRAS project 342412). Anonymised study data will be stored on the Dementia Platform UK (DPUK) Data Portal (https://portal.dementiasplatform.uk) and made available through a managed access process, subject to the DPUK Data Access Agreement.
Related Concept Videos
Dementia l: Introduction
Dementia
The progression of dementia is generally gradual.
Alzheimer Disease l: Introduction
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer Disease ll: Pathophysiology
